Abstract: The present disclosure is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof and compounds of Formula (II), or pharmaceutically acceptable salts thereof, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for the treatment of disorders such as cancer and autoimmune disease.

Abstract: A cancer treatment comprises the administration of a pro-drug compound identified by an in silico candidate identification screening. The pro-drug candidates are selected from a data base and calculations are carried out on the association of the pro-drug candidates to form a complex with a metal ion and a proteasome active site. The pro-drug inhibits the active site of the proteasome in the presence of the metal ion and has little or no effect in the absence of the metal ion. The pro-drug can be: 3,4-dihydroxybenzoic acid; galloflavin; 2-{[(carbamoylsulfanyl)acetyl]amino}benzoic acid; 6,7-Dihydroxycoumaranone; 3,6-bis(hydroxymethyl)pyridazin-4(1H)-one; and 4?,5,7-trihydroxyisoflavone, for binding with copper ion and proteasome.